Sterling Capital Management LLC increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 55.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,144 shares of the medical research company’s stock after buying an additional 408 shares during the period. Sterling Capital Management LLC’s holdings in Bio-Rad Laboratories were worth $376,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. Retirement Systems of Alabama raised its stake in shares of Bio-Rad Laboratories by 416.9% in the 3rd quarter. Retirement Systems of Alabama now owns 23,260 shares of the medical research company’s stock valued at $7,782,000 after buying an additional 18,760 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Bio-Rad Laboratories by 95.6% during the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after purchasing an additional 21,669 shares during the period. GAMMA Investing LLC lifted its stake in Bio-Rad Laboratories by 24.3% during the fourth quarter. GAMMA Investing LLC now owns 665 shares of the medical research company’s stock worth $218,000 after purchasing an additional 130 shares during the period. Diversified Trust Co acquired a new stake in Bio-Rad Laboratories during the fourth quarter valued at approximately $958,000. Finally, Harbor Capital Advisors Inc. grew its stake in shares of Bio-Rad Laboratories by 4.3% in the 4th quarter. Harbor Capital Advisors Inc. now owns 7,824 shares of the medical research company’s stock valued at $2,570,000 after purchasing an additional 321 shares during the period. 65.24% of the stock is currently owned by institutional investors and hedge funds.
Bio-Rad Laboratories Price Performance
Shares of BIO stock opened at $238.02 on Friday. Bio-Rad Laboratories, Inc. has a 52 week low of $215.38 and a 52 week high of $387.99. The stock has a market capitalization of $6.67 billion, a PE ratio of -3.66 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock’s fifty day moving average is $255.62 and its 200-day moving average is $311.59.
Wall Street Analysts Forecast Growth
BIO has been the subject of several analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating on the stock in a report on Thursday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $380.20.
Read Our Latest Analysis on BIO
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Recommended Stories
- Five stocks we like better than Bio-Rad Laboratories
- Election Stocks: How Elections Affect the Stock Market
- J.B. Hunt Transport Overcorrects Into a Buying Opportunity
- How to Use the MarketBeat Stock Screener
- AppLovin: Can Record Profits Overcome Market Skepticism?
- What is the Nasdaq? Complete Overview with History
- MarketBeat Week in Review – 04/14 – 04/18
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.